Trellus Health to Bring Holistic Support to
Patients, Working With a Pharmaceutical Company
LONDON and NEW
YORK, Jan. 14, 2025 /PRNewswire/ -- Trellus
Health plc (AIM: TRLS), a healthcare company delivering Trellus
Elevate™, a digital platform that integrates data analytics with
personalized, scientifically proven resilience programs and
value-based solutions to manage complex chronic conditions,
announced it has entered into an agreement with Johnson &
Johnson Health Care Systems Inc. to support a pilot in the US to
assess the potential for the Trellus Elevate program to support
patients with moderately to severely active inflammatory bowel
disease (IBD).
As part of the agreement, Trellus Health® will receive an
undisclosed upfront licensing fee, along with a fixed monthly
management fee. The one-year collaboration will provide eligible
patients prescribed a Johnson & Johnson therapy access to
Trellus Elevate™.
Patient Support Programs (PSPs), provided by pharmaceutical
companies, are designed to help patients manage their medical
conditions alongside prescription therapies by offering resources
and tailored support. By integrating Trellus Elevate™ into such a
program, patients are offered the tools and confidence to navigate
the emotional and physical challenges of their condition, stay
engaged, adhere to treatment plans, and take control of their
health journey.
Dr. Marla Dubinsky, Chief
Executive Officer of Trellus Health,
said:
"We identified the
pharmaceutical sector as a key strategic vertical in our September
interim results and are excited to announce our first major
collaboration in this vertical. Trellus Elevate™ provides a
seamless, end-to-end solution from clinical trials to
commercialisation, leveraging our proprietary resilience-based
approach to drive trial and patient support success.
"We have reached a therapeutic ceiling with many existing
treatments for IBD and it is only by addressing both the mind and
body that we can truly break through that barrier. Managing and
adhering to treatment regimens for lifelong, incurable immune
conditions like IBD can be overwhelming for patients, making
comprehensive support essential. By providing holistic wraparound
care, we can help patients stay on track with their therapies and
empower them to thrive. We look forward to working with
Johnson & Johnson and leveraging our Trellus Elevate™ platform
and our innovative methodology to help support
patients' needs."
This announcement contains inside information for the purposes
of article 7 of the Market Abuse Regulation (EU) 596/2014 as
amended by regulation 11 of the Market Abuse (Amendment) (EU Exit)
Regulations 2019/310. Upon the publication of this
announcement, this inside information is now considered to be in
the public domain.
About Trellus Health plc
(www.trellushealth.com)
Trellus Health
(AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services for chronic condition management
that prioritises improved outcomes and member experiences while
managing costs of care.
Trellus Health® integrates its proprietary resilience-based
methodology with the technology, tools, and expert coaching and
educator team to deliver Trellus Elevate™, a whole-person
technology-enhanced experience that meets an individual's unique
needs and empowers them to master their physical and emotional
health. Trellus Elevate™ delivers clinically proven solutions that
alleviate disease burden, foster resilient self-management skills,
and promote positive health attitudes, beliefs, and behaviours.
These transformative changes improve outcomes and empower
individuals to thrive while managing chronic conditions.
The Company's proven whole person approach recognises the
interconnectedness of various aspects of a person's life and aims
to address the whole spectrum of factors that influence behaviour,
to promote comprehensive well-being and human flourishing in a way
that aligns with value-based care. Trellus Health's approach
enables better health outcomes in a member-centric, personalised
and comprehensive holistic solution.
The Company was founded by Mount
Sinai faculty members Marla C.
Dubinsky, MD and Laurie
Keefer, PhD, both experts at treating and healing both the
physical and emotional impacts of IBD and have been innovators for
whole-person healthcare for a combined 50 years.
The Company is initially focusing on chronic costly specialty
conditions that have high mental health burden, such as
inflammatory bowel disease ("IBD") which includes the chronic
incurable conditions of Crohn's disease and ulcerative colitis.
Given the common emotional and mental health struggles often
experienced by individuals suffering from a variety of chronic
conditions, Trellus Health considers its approach to have potential
utility and demand across many conditions.
The Trellus Elevate™ program incorporates the GRITT™ methodology
and learnings on resilience from clinical research and practice
conducted at the Mount Sinai IBD Center for more than seven years.
This proprietary, resilience-driven methodology has been
scientifically validated to demonstrate meaningful improvements in
patient outcomes, 71% reduction in Emergency Department (A&E)
visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for
significant cost savings for healthcare payers and health systems.
Patients with IBD managed with the proprietary resilience
methodology also experienced a 49% reduction in required opioid use
and a 73% reduction in corticosteroid use 12 months following
starting the program which is a major indicator of improved health
outcomes1.
Shares in Trellus Health were admitted to trading on AIM in
May 2021, under the ticker TRLS. For
more information on Trellus Health, visit:
www.trellushealth.com
1 Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trellus-health-to-bring-holistic-support-to-patients-working-with-a-pharmaceutical-company-302349940.html
SOURCE Trellus Health Inc.